Drug Trial Radar · NCT01254552
Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis
Last checked: Nov 20, 2026Latest source record: May 31, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
351
Actual
Start
Aug 2010
Primary completion
Sep 2011
Study completion Oct 2016
Sponsor
- Lead sponsor
- GuerbetIndustry
- Sponsor type
- Industry
- First posted
- Dec 6, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 50 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study aimed to prospectively investigate the prevalence of myocardial scar on Dotarem-enhanced Cardiovascular Magnetic Resonance Imaging (MRI) in asymptomatic patients with type-2 Diabetes Mellitus and to assess its correlation with subclinical coronary artery disease on Cardiac Computed Tomography Angiography (CCTA).
Conditions
- Type 2 Diabetes Mellitus
- Coronary Atherosclerosis
Interventions
iobitridolDrug
Xenetix 350 was administered at a dose up to 180 ml, according to the patient's body weight measured on the day of administration.
gadoterate meglumineDrug
Dotarem was administered at a dose of 0.1 mmol/kg body weight (0.2 ml/kg body weight)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prevalence of Occult Myocardial Scar on Delayed-enhanced MRI in Asymptomatic Patients With Type 2 Diabetes MellitusTime frame: From 1 week to 2 months (after the collection of data corresponding to cardiac MRI and CCTA examinations)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.